11.Operating expenses: Research and development expenses: | | | | | | | December 31, 2025 | | December 31, 2024 | | | $ | | $ | Salaries and management fees | | 3,359 | | 2,687 | Discovery expenses | | 682 | | 698 | Preclinical expenses | | 2,160 | | 5,420 | Chemistry, manufacturing controls | | 1,117 | | 2,495 | Clinical expenses | | 9,600 | | 2,459 | Stock-based compensation | | 1,508 | | 600 | Total research and development expenses | | 18,426 | | 14,359 |
General and administrative: | | | | | | | December 31, 2025 | | December 31, 2024 | | | $ | | $ | Salaries and management fees | | 3,337 | | 2,723 | Professional fees | | 2,374 | | 1,688 | Other operating expenses | | 590 | | 572 | Stock-based compensation | | 1,727 | | 1,041 | Depreciation | | 5 | | 15 | Total general and administrative expenses | | 8,033 | | 6,039 |
|